Protein tyrosine phosphatase receptor type γ is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia

Cancer Research

Volumn 70, Issue 21, 2010, Pages 8896-8906

  Della Peruta, Marco ^a   Martinelli, Giovanni ^b   Moratti, Elisabetta ^a   Pintani, Davide ^a   Vezzalini, Marzia ^a   Mafficini, Andrea ^a   Grafone, Tiziana ^b   Iacobucci, Ilaria ^b   Soverini, Simona ^b   Murineddu, Marco ^c   Vinante, Fabrizio ^a   Tecchio, Cristina ^a   Piras, Giovanna ^c   Gabbas, Attilio ^c   Monne, Maria ^c   Sorio, Claudio ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c SAN FRANCESCO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BCR ABL PROTEIN; CD34 ANTIBODY; MESSENGER RNA; PROTEIN TYROSINE PHOSPHATASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; BONE MARROW; CANCER REGRESSION; CELL LINE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKOCYTE; MALE; MEGAKARYOCYTE; METHYLATION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; DNA METHYLATION; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LUCIFERASES; MALE; MICE; MICE, NUDE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 5; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78449284644     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0258     Document Type: Article

References (44)

1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
2. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164-72.
3. Meyn MA III, Wilson MB, Abdi FA, et al. Src family kinases phosphorylate the Bcr-Abl SH3-2 region and modulate Bcr-Abl transforming activity. J Biol Chem 2006;281:30907-16.
4. LaMontagne KR, Jr., Flint AJ, Franza BR, Jr., Pandergast AM, Tonks NK. Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo. Mol Cell Biol 1998;18:2965-75.
5. Bruecher-Encke B, Griffin JD, Neel BG, Lorenz U. Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation. Leukemia 2001;15:1424-32.
6. Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005;8:355-68.
7. Motiwala T, Majumder S, Ghoshal K, et al. PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells. J Biol Chem 2009;284:455-64.
8. Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 2006;7:833-46.
9. Sorio C, Melotti P, D'Arcangelo D, et al. Receptor protein tyrosine phosphatase γ, Ptpγ, regulates hematopoietic differentiation. Blood 1997;90:49-57.
10. Mafficini A, Vezzalini M, Zamai L, et al. Protein tyrosine phosphatase γ (PTPγ) is a novel leukocyte marker highly expressed by CD34+ precursors. Biomarker Insights 2007;2:217-24.
11. Lissandrini D, Vermi W, Vezzalini M, et al. Receptor-type protein tyrosine phosphatase γ (PTP{γ}), a new identifier for myeloid dendritic cells and specialized macrophages. Blood 2006;108:4223-31.
12. Barnea G, Silvennoinen O, Shaanan B, et al. Identification of a carbonic anhydrase-like domain in the extracellular region of RPTPγ defines a new subfamily of receptor tyrosine phosphatases. Mol Cell Biol 1993;13:1497-506.
13. LaForgia S, Morse B, Levy J, et al. Receptor protein-tyrosine phosphatase γ is a candidate tumor suppressor gene at human chromosome region 3p21. Proc Natl Acad Sci U S A 1991;88:5036-40.
14. Lubinski J, Hadaczek P, Podolski J, et al. Common regions of deletion in chromosome regions 3p12 and 3p14.2 in primary clear cell renal carcinomas. Cancer Res 1994;54:3710-3.
15. van Niekerk CC, Poels LG. Reduced expression of protein tyrosine phosphatase γ in lung and ovarian tumors. Cancer Lett 1999;137:61-73.
16. Vezzalini M, Mombello A, Menestrina F, et al. Expression of transmembrane protein tyrosine phosphatase γ (PTPγ) in normal and neoplastic human tissues. Histopathology 2007;50:615-28.
17. Wang Z, Shen D, Parsons DW, et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 2004;304:1164-6.
18. Furuta J, Nobeyama Y, Umebayashi Y, Otsuka F, Kikuchi K, Ushijima T. Silencing of peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. Cancer Res 2006;66:6080-6.
19. Wang JF, Dai DQ. [Difference in methylation of genomic DNA between gastric primary cancer and lymph nodes with metastatic gastric cancer]. Zhonghua Yi Xue Za Zhi 2006;86:536-9.
20. van Doorn R, Zoutman WH, Dijkman R, et al. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, p73. J Clin Oncol 2005;23:3886-96.
21. Cheung AK, Lung HL, Hung SC, et al. Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma. Cancer Res 2008;68:8137-45.
22. Klein E, Ben-Bassat H, Neumann H, et al. Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer 1976;18:421-31.
23. Ogura M, Morishima Y, Ohno R, et al. Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. Blood 1985;66:1384-92.
24. Ohkubo T, Kamamoto T, Kita K, Hiraoka A, Yoshida Y, Uchino H. A novel Ph1 chromosome positive cell line established from a patient with chronic myelogenous leukemia in blastic crisis. Leuk Res 1985;9:921-6.
25. Seigneurin D, Champelovier P, Mouchiroud G, et al. Human chronic myeloid leukemic cell line with positive Philadelphia chromosome exhibits megakaryocytic and erythroid characteristics. Exp Hematol 1987;15:822-32.
26. Sorio C, Mendrola J, Lou Z, LaForgia S, Croce CM, Huebner K. Characterization of the receptor protein tyrosine phosphatase gene product PTPγ: binding and activation by triphosphorylated nucleosides. Cancer Res 1995;55:4855-64.
27. Liu S, Sugimoto Y, Sorio C, Tecchio C, Lin YC. Function analysis of estrogenically regulated protein tyrosine phosphatase γ (PTPγ) in human breast cancer cell line MCF-7. Oncogene 2004;23:1256-62.
28. Witt O, Sand K, Pekrun A. Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. Blood 2000;95:2391-6.
29. Belhacene N, Maulon L, Guerin S, et al. Differential expression of the Kell blood group and CD10 antigens: two related membrane metallopeptidases during differentiation of K562 cells by phorbol ester and hemin. FASEB J 1998;12:531-9.
30. Hock RA, Miller AD. Retrovirus-mediated transfer and expression of drug resistance genes in human haematopoietic progenitor cells. Nature 1986;320:275-7.
31. Golas JM, Arndt K, Etienne C, et al. SKI-606, a 4-anilino-3-quinoline- carbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003;63:375-81.
32. Mauri P, Scarpa A, Nascimbeni AC, et al. Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers. FASEB J 2005;19:1125-7.
33. Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 1994;84:2912-8.
34. ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia. Blood 1994;84:1731-6.
35. Hamilton A, Elrick L, Myssina S, et al. BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry. Leukemia 2006;20:1035-9.
36. Horita M, Andreu EJ, Benito A, et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 2000;191:977-84.
37. Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009;113:1619-30.
38. Frank DA, Varticovski L. BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia 1996;10:1724-30.
39. Ilaria RL, Jr., Van Etten RA. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996;271:31704-10.
40. Cotta CV, Bueso-Ramos CE. New insights into the pathobiology and treatment of chronic myelogenous leukemia. Ann Diagn Pathol 2007;11:68-78.
41. Chien W, Tidow N, Williamson EA, et al. Characterization of a myeloid tyrosine phosphatase, Lyp, and its role in the Bcr-Abl signal transduction pathway. J Biol Chem 2003;278:27413-20.
42. Shimizu T, Miyakawa Y, Iwata S, et al. A novel mechanism for imatinib mesylate (STI571) resistance in CML cell line KT-1: role of TC-PTP in modulating signals downstream from the BCR-ABL fusion protein. Exp Hematol 2004;32:1057-63.
43. Neviani P, Santhanam R, Oaks JJ, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007;117:2408-21.
44. Oki Y, Kantarjian HM, Gharibyan V, et al. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 2007;109:899-906.